Becker Lab retweeted
In this Q&A with @DrugTargetRev, our cofounder Dr. Lev Becker shares more about how N17350 selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms.
bit.ly/3SgxknO
Becker Lab retweeted
We will be presenting at #ImmunoSeries on our lead drug candidate, N17350, which is an emerging therapeutic modality that selectively kills any #cancer cells and stimulates anti-tumor immunity.
For the full @ImmunoOncConf agenda visit: oxfordglobal.co.uk/immuno-se…
Becker Lab retweeted
We will be presenting at #SITC23 our latest data on our lead drug candidate, N17350, showing a unique combination of potent and selective #cancer killing activity to eradicate #tumors independent of genetics or anatomical origin.
onchillespharma.com/2023/09/…
Becker Lab retweeted
The University of Chicago Medicine’s Cancer Program is one of the top-ranked specialties in the nation and the best in Illinois, according to the latest U.S. News & World Report.
ow.ly/2OaM50Pq3bs
Becker Lab retweeted
We’re excited to present today at #AACR23 new preclinical data for our lead candidate N17350, which possesses unique therapeutic characteristics and may be a major new treatment modality in #immunooncology.
See the press release & poster here: bit.ly/409tWvG
Becker Lab retweeted
Check out 60 minutes tonight. Thanks to hardworking neuroscientists, amazing patients and especially monkeys, BCI is helping people every day. @Wa_NPRC @slimanjbensmaia cbsnews.com/video/feeling-of…
Becker Lab retweeted
Today we disclosed our 1st drug development candidate, N17350, a first-in-class biologic to leverage #neutrophil biology and broadly treat #cancer. We also expanded our platform to design new therapeutics to modulate M2-like tumor-associated #macrophages.
onchillespharma.com/2022/12/…
Becker Lab retweeted
Tenure Track Assistant Professorship in the Ben May Department for Cancer Research - looking for talented applicants focused on Mechanistic Aspects of Prostate Cancer or Related Areas. EOE/Vet/Disability. Apply here:
apply.interfolio.com/98164
Becker Lab retweeted
Today we welcome Chang Cui, Ph.D., to the team! Prior to joining us, @PurrChangC advanced foundational research in @LevBecker’s lab of a novel #neutrophilpathway with broad #anticancer potential for new #cancer #immunotherapy treatments.
An overdue congratulations to Dr. Chang Cui who recently defended her thesis on leveraging macrophages to develop cancer therapeutics! We are so proud of her and so excited to see all the great things to come! @PurrDrCc @LevBecker @UCCancerCenter @UChicagoImmuno 🎉🎉 #Retweet
Becker Lab retweeted
Hi #metabolism twitter. UChicago is looking for a director to run the new Metabolomics Platform providing metabolite and metabolic flux analysis to Chicago metabolism community. Details: uchicago.wd5.myworkdayjobs.c… Please forward to any colleagues that might be interested!
Becker Lab retweeted
We expanded our scientific leadership team: Christopher Twitty, Ph.D. as CSO, Sonia Feau, Ph.D., as Dir. of Biology, and Ingrid Joseph, DVM, Ph.D., as SVP, Preclinical Development. They will help advance our first-in-class novel neutrophil therapeutics.
onchillespharma.com/2021/10/…
Becker Lab retweeted
#ResearchWatch Neutrophil elastase (ELANE), a serine protease, selectively kills tumor cells. @LevBecker @UCCancerCenter #Immunology
bit.ly/3uE5W49
Becker Lab retweeted
Find out about a protease with far-reaching anti-cancer effects in this highlight of research by @LevBecker et al. go.nature.com/3itOZH9
Becker Lab retweeted
Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway
onchillespharma.com/2021/06/…
#biotech #sandiego #financing #cancer #neutrophils #anticancerprotein #biologic #cancerresearch #ELANE
